Allergan to acquire University of Sydney spinoff Elastagen

Allergan plc agreed to acquire Elastagen Pty Ltd, a clinical-stage company developing medical device products based on recombinant tropoelastin, for an upfront payment of US$95 million plus contingent payments.

“Elastagen Pty Ltd, a clinical stage company developing medical device products based on recombinant tropoelastin, today announced that it has entered into a definitive agreement under which Allergan plc, a leading global biopharmaceutical company, has agreed to acquire Elastagen.”sydney.edu.au

• 1 source
• sydney.edu.auAllergan to acquire University of Sydney spinoff Elastagen - The University of SydneyFeb 9, 2018

Summarized from public sources; check the original articles before acting on it.